Neximmune Stock Analysis

NEXI -  USA Stock  

USD 10.67  1.31  10.93%

The big decline in price over the last few months for Neximmunemay encourage stockholders to take a closer look at the firm as it is trading at a share price of 10.67 on 30,800 in trading volume. The company directors and management failed to add value to investors and positioning the firm supply of money to exploit market volatility in June. However, diversifying your holdings with Neximmune or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.37. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Neximmune partners.
Additionally, see Stocks Correlation.

Search Stock Analysis 

The Neximmune stock analysis report makes it easy to digest most publicly released information about Neximmune and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Neximmune Stock analysis module also helps to analyze the Neximmune price relationship with some important fundamental indicators such as market cap and management efficiency.

Neximmune Stock Analysis Notes

The company had not issued any dividends in recent years. NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. NexImmune, Inc. was founded in 2011 and is headquartered in Gaithersburg, Maryland. Neximmune operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. To find out more about Neximmune contact the company at 301 825 9810 or learn more at

Neximmune Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Neximmune's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Neximmune or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Neximmune generates negative expected return over the last 90 days
Neximmune has high historical volatility and very poor performance
Neximmune has high likelihood to experience some financial distress in the next 2 years
The company currently holds 32.15 K in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Neximmune has a current ratio of 0.25, indicating that it has a negative working capital and may not be able to pay financial obligations when due.
Net Loss for the year was (30.15 M).
Neximmune currently holds about 10.14 M in cash with (24.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.07.
Neximmune has a frail financial position based on the latest SEC disclosures
Latest headline from Neximmune Inc gains 0.08 percent for July 14 -

Neximmune Upcoming and Recent Events

Earnings reports are used by Neximmune to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Neximmune previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report16th of August 2021
Next Fiscal Quarter End30th of June 2021
Next Fiscal Year End30th of March 2022
Last Quarter Report31st of March 2021
Last Earning Announcement30th of June 2020

Neximmune Largest EPS Surprises

Earnings surprises can significantly impact Neximmune's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Neximmune SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Neximmune prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Neximmune investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Neximmune specific information freely available to individual and institutional investors to make a timely investment decision.
17th of May 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
12th of April 2021
Unclassified Corporate Event
31st of March 2021
Financial Statements and Exhibits. Unclassified Corporate Event. Results of Operations and Financial Condition
17th of February 2021
Financial Statements and Exhibits. Other Events. Amendments to Articles of Incorporation or Bylaws; and/or Change in Fiscal Year

Neximmune Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Neximmune is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Neximmune backward and forwards among themselves. Neximmune's institutional investor refers to the entity that pools money to purchase Neximmune's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Arrowmark Colorado Holdings LlcCommon Shares2.6 M49.5 M
Artal Group SaCommon Shares1.2 M22.9 M
Slate Path Capital LpCommon Shares925 K17.6 M
Allen Operations LlcCommon Shares635.9 K12.1 M
Suvretta Capital Management LlcCommon Shares579.3 K11.1 M
Fmr LlcCommon Shares525 K10 M
Adage Capital Partners Gp LlcCommon Shares500 K9.5 M
Note, although Neximmune's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Neximmune Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 500.71 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Neximmune's market, we take the total number of its shares issued and multiply it by Neximmune's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Neximmune Profitablity

Neximmune's profitability indicators refer to fundamental financial ratios that showcase Neximmune's ability to generate income relative to its revenue or operating costs. If, let's say, Neximmune is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Neximmune's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Neximmune's profitability requires more research than a typical breakdown of Neximmune's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2021
Return on Average Assets(2.65) (2.86) 
Return on Average Equity 0.59  0.58 
Return on Invested Capital 268.31  217.91 

Management Efficiency

The current Return on Average Assets is estimated to decrease to -2.86. The current Return on Average Equity is estimated to decrease to 0.58. Neximmune Assets Non Current are most likely to increase significantly in the upcoming years. The last year's value of Assets Non Current was reported at 2.91 Million. The current Tangible Assets Book Value per Share is estimated to increase to 9.32, while Return on Average Assets are projected to decrease to (2.86) . Neximmune management efficiency ratios could be used to measure how well neximmune manages its routine affairs as well as how well it operates its assets and liabilities.
Last ReportedProjected for 2021
Book Value per Share(55.29) (59.65) 
Tangible Assets Book Value per Share 9.01  9.32 
Tangible Asset Value11.3 M11.4 M

Technical Drivers

As of the 24th of July, Neximmune secures the mean deviation of 2.58, and Risk Adjusted Performance of (0.16). In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Neximmune, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We have analyzed and interpolated nineteen technical drivers for Neximmune, which can be compared to its peers in the industry. Please verify Neximmune coefficient of variation, as well as the relationship between the treynor ratio and semi variance to decide if Neximmune is priced some-what accurately, providing market reflects its recent price of 10.67 per share. Given that Neximmune has jensen alpha of (0.79), we recommend you to check Neximmune's last-minute market performance to make sure the company can sustain itself at a future point.

Neximmune Price Movement Analysis

The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. View also all equity analysis or get more info about mavp overlap studies indicator.

Neximmune Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Neximmune insiders, such as employees or executives, is commonly permitted as long as it does not rely on Neximmune's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Neximmune insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Neximmune Predictive Daily Indicators

Neximmune intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Neximmune stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Neximmune Forecast Models

Neximmune time-series forecasting models is one of many Neximmune's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Neximmune's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Neximmune Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Neximmune stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Neximmune shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Neximmune. By using and applying Neximmune Stock analysis, traders can create a robust methodology for identifying Neximmune entry and exit points for their positions.
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. NexImmune, Inc. was founded in 2011 and is headquartered in Gaithersburg, Maryland. Neximmune operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.

Current Neximmune Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Neximmune analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Neximmune analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
Neximmune current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Neximmune analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Neximmune stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Neximmune, talking to its executives and customers, or listening to Neximmune conference calls.
Neximmune Analyst Advice Details

Neximmune Stock Analysis Indicators

Neximmune stock analysis indicators help investors evaluate how Neximmune stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Neximmune shares will generate the highest return on investment. By understating and applying Neximmune stock analysis, traders can identify Neximmune position entry and exit signals to maximize returns.
Quick Ratio0.13
Fifty Two Week Low20.16
Fifty Two Week High28.00
Average Daily Volume Last 10 Day3.49M
Average Daily Volume In Three Month3.49M
Enterprise Value To Ebitda-2.97
Fifty Day Average25.33
Two Hundred Day Average25.33
Additionally, see Stocks Correlation. Note that the Neximmune information on this page should be used as a complementary analysis to other Neximmune's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

Complementary Tools for Neximmune Stock analysis

When running Neximmune price analysis, check to measure Neximmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neximmune is operating at the current time. Most of Neximmune's value examination focuses on studying past and present price action to predict the probability of Neximmune's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Neximmune's price. Additionally, you may evaluate how the addition of Neximmune to your portfolios can decrease your overall portfolio volatility.
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Bond Directory
Find actively traded corporate debentures issued by US companies
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
The market value of Neximmune is measured differently than its book value, which is the value of Neximmune that is recorded on the company's balance sheet. Investors also form their own opinion of Neximmune's value that differs from its market value or its book value, called intrinsic value, which is Neximmune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neximmune's market value can be influenced by many factors that don't directly affect Neximmune underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neximmune's value and its price as these two are different measures arrived at by different means. Investors typically determine Neximmune value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neximmune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.